LAUSR

Background: The coronavirus disease 2019 pandemic (COVID-19) has brought great public health challenges into our lives To date, there has been no specific therapeutic protocol for this disease, which requires a study with high-quality evidence Objectives: To analyze clinical trials on COVID-19 in Brazil Methods: Documentary research was conducted on the clinical trial registration platform For the search strategy, the “COVID-19” keyword was established in the “condition or disease” section and “Brazil” in the “country” section No limit on the search period was considered Data were analyzed and presented using descriptive statistics Results: Of the 81 registered clinical trials, 48 met the eligibility criteria The sample size ranged from 10 to 3,000 individuals Most studies recruited individuals aged 18-64 years (48 5%) and > 65 years (48 5%) Regarding the study design, randomized (91 6%), parallel (89 5%), quadruple-blind (39 6%), and therapeutic (97 9%) types were more frequent Most studies used standard two-arm trial (70 8%), used drugs (79 2%), placebo (58 3%), and were sponsored by pharmaceutical/biotechnology companies and universities with 33 3% and 29 2%, respectively Conclusions: Clinical trials under development in Brazil on COVID-19 are mostly carried out with adult and elderly participants, and regarding the study design, have a predominance of randomized allocation, parallel model, quadruple-blind masking with a therapeutic purpose Most studies use antithrombotic agents or combinations of antithrombotic agents © 2020, Author(s)